CBMGCell Biology and Molecular Genetics (academic program; University of Maryland; College Park, MD)
CBMGCognitive Brain Mapping Group (Northwestern University; Evanston, IL)
CBMGCoal Bed Methane Gas
CBMGCorporate Benefit Management Group (Memphis, TN)
References in periodicals archive ?
CBMG expects to become the first company to install GE's FlexFactory for cell therapy, and anticipates that the FlexFactory will be operational in the CBMG-GE Joint Laboratory of Cell Therapy by the end of 2018.
This is a productivity revolution in the CAR-T space this new generation of semi-automated and standardized CAR-T manufacturing capabilities created by GE Healthcare and CBMG may allow cell therapy to provide an optimal platform and opportunity for general oncology patients.
Recently, CBMG announced that its new Zhangjiang facility, together with an expanded Wuxi, and Beijing GMP-facilities, will have a combined 70,000 square feet for development and production.
CBMG is a developer of cellular medicine technologies that include autologous and allogeneic platforms.
CBMG recently announced promising interim 3-month safety data from its Phase 1 clinical trial in China for AlloJoin.
Michael James, president and CEO of CBMG said, "It is a great personal pleasure to be able to set up business with CNPIC, after many years of working together in various ways with our friends there.
Adrienne Marie Ward of Ellenoff Grossman & Schole LLP (EGS) will serve as lead defense counsel for CBMG and its officers.
In a partial response to "false statements and allegations made by ["short seller"] Pump Stopper on April 7, 2015," CBMG published the following on its Web site:
CBMG said it is a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases.
The CBMG concept responds directly to the APEC declaration in Vladivostok, Russian 2012, in which the APEC leaders summarized their keynote as Integrate to Grow, Innovate to Prosper .
CBMG, announced interim 24-week clinical data from the Phase 2b trial of its Re-Join human adipose-derived mesenchymal progenitor cell (haMPC) therapy for knee osteoarthritis (KOA).
Pump Stopper -- author of the detailed analytical piece on CBMG published on the Seeking Alpha Web site -- concludes his remarks as follows: